Physician

Noman Rafique, M.D.

According to 2025 Medicare claims, Noman Rafique, M.D. (NPI: 1043215676) practices hematology/oncology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is TRI-COUNTY HEMATOLOGY & ONCOLOGY ASSOCIATES INC (NPI: 1578600201; TIN: 341294692) and primary practice location at 44646-9118. Rafique is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Rafique's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 780 traditional Medicare patients, billed 232,490 HCPCS/CPT codes, and received $3,111,229 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,915 prescription claims across 572 beneficiaries totaling $16,938,073 in drug costs, led by Xtandi (Enzalutamide). 2019 DME data shows 62 claims. Open Payments data shows 152 records totaling $60,412. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $3,144,365 to $16,938,073. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $3,122 to $2,567.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	717	151,132	$2,136,700
2016	808	272,191	$3,081,362
2017	853	239,770	$3,108,373
2018	905	312,015	$3,700,666
2019	1,065	339,926	$4,552,076
2020	825	226,432	$3,342,528
2021	764	230,015	$3,446,437
2022	835	223,621	$2,919,428
2023	779	224,338	$2,761,357
2024	780	232,490	$3,111,229

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	487	3,100	$3,144,365
2016	445	2,750	$3,936,787
2017	449	2,639	$4,637,999
2018	507	2,986	$5,896,702
2019	579	3,373	$8,077,880
2020	538	3,078	$8,672,096
2021	534	3,148	$8,942,295
2022	558	3,269	$12,030,677
2023	567	3,673	$16,796,986
2024	572	3,915	$16,938,073

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	100	$42,250
2016	N/R	113	$30,227
2017	11	118	$25,268
2018	N/R	111	$11,515
2019	N/R	62	$7,926
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	347	983	$97
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	349	510	$61
80053	Blood test, comprehensive group of blood chemicals	402	833	$10
36415	Insertion of needle into vein for collection of blood sample	609	2,381	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	601	2,486	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	118	3,540	$1,620,022
Pomalyst	Pomalidomide	54	1,512	$1,176,891
Revlimid	Lenalidomide	57	1,596	$1,014,450
Lenalidomide	Lenalidomide	67	1,876	$897,933
Kisqali	Ribociclib Succinate	54	1,498	$841,487

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	139	$2,869	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	13	$57,543	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Noman Rafique, M.D.?

Tedicare shows public-source Medicare data for Noman Rafique, M.D. (NPI 1043215676), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Noman Rafique, M.D. have ACO affiliation data?

Noman Rafique, M.D. is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Noman Rafique, M.D.?

Noman Rafique, M.D. is linked to TRI-COUNTY HEMATOLOGY & ONCOLOGY ASSOCIATES INC (billing NPI 1578600201) in the available physician profile data.

Does Noman Rafique, M.D. have Open Payments data?

Noman Rafique, M.D. has 152 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.